Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation (MS-PEKOS)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06668324

Acronym

MS-PEKOS

Enrollment

134

Registered

2024-10-31

Start date

2024-11-15

Completion date

2025-09-05

Last updated

2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

1. Ability to use a mobile device or computer with broadband internet access (or data streaming available) 2. Ability to read, understand, and respond in English 3. Adult aged 18 years of age or over at the time of the survey 4. Self-confirmed diagnosis of MS 5. Prescribed either OMB or OCR SC and will receive their first injection (Day 0) followed by completing the study survey between Day 1 and Day 7

Exclusion criteria

1. Participated in an OMB or OCR randomized clinical trial 2. Previously treated with OMB or OCR SC 3. Cognitive impairment that impacts the patient's ability to participate in a survey study

Design outcomes

Primary

Measure	Time frame	Description
Proportion of patients reported local injection-related reaction post first injection	Day 1- 7 post first injection, at the time of survey completion	Proportion of patients reported local injection-related reactions (including pain, erythema, induration, and pruritus) by using modified Defense and Veterans Pain Rating Scale (DVPRS)

Secondary

Measure	Time frame	Description
Proportion of patients in a 5-Likert scale for satisfaction on injection-related experience (post first injection)	Day 1 - 7 post first injection, at the time of survey completion	Proportion of patients in a 5-Likert scale (extremely dissatisfied, dissatisfied, neutral, satisfied, and extremely satisfied) for satisfaction on injection-related experience
Proportion of patients reported local injection-related reaction post second injection	Day 1- 7 post second injection, at the time of survey completion	Proportion of patients reported local injection-related reactions (including pain, erythema, induration, and pruritus) by using modified Defense and Veterans Pain Rating Scale (DVPRS)
Proportion of patients in a 5-Likert scale for satisfaction on injection-related experience (post second injection)	Day 1- 7 post second injection, at the time of survey completion	Proportion of patients in a 5-Likert scale (extremely dissatisfied, dissatisfied, neutral, satisfied, and extremely satisfied) for satisfaction on injection-related experience

Countries

United States

Outcome results